Sarah Scagliarini: Sex disparities in advanced urothelial carcinoma are not a trend but a real gap
Sarah Scagliarini, Medical Oncologist at Antonio Cardarelli National Hospital, posted on LinkedIn about recent paper by Lorena Incorvai et al., titled “Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab” published on Scientific Reports.
Authors: Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, Hideki Takeshita, Jose Carlos Tapia, María Natalia Gandur Quiroga, Elaine Lam, Deniz Tural, Lazar Popovic, Saul Campos-Gomez, Paolo Andrea Zucali, Augusto Mota, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Halima Abahssain, Andrea Benedetto Galosi, Giuseppe Badalamenti, Jindrich Kopecky, Aristotelis Bamias, Johannes Landmesser, Jawaher Ansari, Fabio Calabrò, Francesco Massari, Sebastiano Buti, Joaquim Bellmunt, Matteo Santoni
“Sex disparities in advanced urothelial carcinoma are not a trend but a real gap!
Thanks to Lorena Incorvaia, Matteo Santoni, Joaquim Bellmunt and all ARON project team for this study born from an international collaboration!
Our data of 1039 patients showed that women with metastatic urothelial carcinoma treated with pembrolizumab had shorter OS than men, with a 13% advantage in the 5-year OS rate for male patients.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023